Background
==========

*Shigella* species are an important cause of diarrhea in developing countries. In 2013, the World Health Organization (WHO) reported the diarrheal disease is a leading cause of child mortality and morbidity in the world, and mostly results from contaminated food and water sources. Worldwide, 780 million individuals lack access to improved drinking-water and 2.5 billion lack improved sanitation. Diarrhea due to infection is widespread throughout developing countries. Globally, there are nearly 1.7 billion cases of diarrheal disease every year. Each year diarrhea kills around 760, 000 children under five years of age \[[@B1]\]. Bhutan is a developing country in the South Asia region with decent health care access throughout the country. The current population of the country is around 706,800 with about 80% of the population residing in rural areas. Children under 5 years of age comprise about 10% of the total population with an annual birth cohort of 14,000 \[[@B2]\]. For Bhutan, diarrheal disease is an important public health problem. Treatment for diarrheal disease in the country is empirical rather than evidence based due to the lack of diarrhea etiology data. In the Annual Health Bulletin, Bhutan reported an average of 60,000-70,000 cases of diarrhea and 25,000-30,000 cases of dysentery per year from 2005--2009. The overall incidence of diarrheal diseases in Bhutan during 2010 was 126.6 per 1,000 people. The percentage of diarrhea and dysentery that occurred in children less than 5 years of age for 2009 were 34% and 30%, respectively \[[@B3]\]. Shigellosis has been a notifiable disease in Bhutan since May 2010 with only one case reported \[[@B4]\]. In 2011, a reported diarrhea outbreak probably caused by *Shigella flexneri* occurred during March 2011 in a remote village in Mongar District, Bhutan \[[@B5]\]. During a diarrhea surveillance study in Thimphu, Bhutan from March 2011 to February 2013, *Shigella sonnei* was isolated from children's stool samples more frequently than expected in June and July 2011.

The rapid emergence of multidrug-resistant (MDR) strains is largely due to their ability to acquire and disseminate exogenous genes associated with mobile genetic elements such as, transposons, integrons, plasmids, and genomic islands \[[@B6]\]. Some transposons code for single resistance \[e.g. TEM b-lactamase (Tn*3*), kanamycin (Tn*5*) and tetracycline resistance (Tn*10*)\], but plasmids and transposons coding multiple drug resistance often possess another genetic element, the integron \[[@B7]\]. Integrons are genetic elements that contain the components of a site-specific recombination system that recognizes and captures mobile gene cassettes. Based on the characteristics of their integrase genes, four classes of integrons (classes 1, 2, 3, and 4) have been identified to date \[[@B8]\]. Class 1 and 2 integrons have been frequently reported in studies of human *Shigella*\[[@B9]\]. Antibiotic-resistance plasmids frequently contain genes conferring resistance to several different antibiotics. The ability to recognize and categorize plasmids in homogeneous groups on the basis of their phylogenetic relatedness can be helpful to analyze their distribution in nature, the relationship with the host cell and to discover their evolutionary origin \[[@B10]\].

To further study the multidrug resistance in Thimphu, Bhutan, we characterized *S. sonnei* isolates from children, the genetic basis of antibiotic resistance including class 1 and class 2 integrons, DNA gyrase A mutations and plasmid replicon typing.

Methods
=======

Clinical specimens
------------------

A diarrhea etiology study was conducted at Jigme Dorji Wangchuk National Referral Hospital (JDWNRH) in Thimphu, Bhutan from March 2011 to February 2013. Children 3 months to 5 years of age presenting for clinical care at JDWNRH with a chief complaint of acute diarrhea (3 or more loose stools in the previous 24 hours starting no more than 72 hours before presenting were eligible to provide a stool sample as cases. Children 3 months to 5 years presenting for clinical care at JDWNRH for other causes, who not had a history of diarrhea in the past 2 weeks and had not received antibiotics in the past 3 days were eligible to provide stool samples as controls. The study was approved by the Research Ethics Board of Health (REBH), Bhutan and the Institutional Review Board (IRB), Walter Reed Army Institute of Research (WRAIR). Stool samples were collected from children with verbal informed consent from their parent or guardian.

Specimen processing and identification
--------------------------------------

Stool samples collected in Cary-Blair transport medium were cultured on MacConkey (MAC) and Hektoen Enteric (HE) agar (Becton-Dickinson and Company, Sparks, MD, USA) and subsequently incubated at 37°C overnight. Plates are examined for the presence of colonies resemble to *Shigella* and identified by standard biochemical tests and further serotyped by agglutination test (Denka Seiken, Japan) at the Armed Forces Research Institute of Medical Sciences (AFRIMS) in Bangkok, Thailand \[[@B11]\]. Isolates were stored in Luria-Bertani (LB) broth containing 15% glycerol at -70°C until use.

Antimicrobial susceptibility methods
------------------------------------

The *S. sonnei* isolates were tested for susceptibility to antimicrobial agents by the standard disk diffusion method according to Clinical and Laboratory Standards Institute (CLSI) guideline \[[@B12]\]. Antimicrobial disks included azithromycin (AZM 15 μg), nalidixic acid (NA 30 μg), ciprofloxacin (CIP 5 μg), ampicillin (AM 10 μg), trimethoprim-sulfamethoxazole (SXT 1.25/23.75 μg), ceftriaxone (CRO 30 μg), streptomycin (S 10 μg), and tetracycline (TE 30 μg) (Sensi-Disc; Becton Dickinson, NJ, USA). Minimum inhibitory concentrations (MIC) for AZM, NA, and CIP were also determined by E-test (AB Biodisk, Solna, Sweden). The standard disk diffusion method and MIC were interpreted according to CLSI guideline \[[@B12]\]. Organisms used for quality control of antimicrobial susceptibility testing included *Escherichia coli* ATCC 25922, *Staphylococcus aureus* ATCC 25923, and *Staphylococcus aureus* ATCC 29213. In the absence of CLSI definitive standards for azithromycin (AZM) breakpoints of the family Enterobacteriaceae, interpretive standards as published by the disk manufacturer for *Staphylococcus* spp. was used (BBL package insert; Becton-Dickinson and Company, Sparks, MD, USA). Multidrug-resistant (MDR) *S. sonnei* strains were defined as strains that were resistant to two or more antimicrobial agents.

Pulsed-field gel electrophoresis (PFGE)
---------------------------------------

Pulsed-field gel electrophoresis (PFGE) was performed according to the One-Day (24--28 h) Standardized Laboratory Protocol for Molecular Subtyping by PFGE \[[@B13]\] with minor modifications. The cell density of each isolate was adjusted by spectrophotometer (Bio-Rad, Hercules, CA, USA). Plug slices of samples and *Salmonella* Braenderup H9812 universal size standard were prepared for *Xba*I digestion and loaded on 1% SeaKem Gold agarose (Lonza, Rockland, ME, USA) with 0.5x TBE pH 8.3 (890 mM Tris, 890 mM Borate, 20 mM EDTA). The gel was electrophoresed by CHEF Mapper system (Bio-Rad, Hercules, CA, USA). The electrophoresis conditions for *Xba*I digestion were auto algorithm mode, 30--600 kb for molecular weight range, and 19 h for run time. The gel images were captured by a gel documentation system (Syngene, Cambridge, UK). Combined dendrogram of PFGE and antimicrobial susceptibility were generated by BioNumerics Software version 6.0 (Applied Maths, Kortrijk, Belgium), UPGMA (Unweighted Pair Group Method with Arithmetic Mean) type and Dice coefficient with 1.0% optimization and tolerance.

Plasmid analysis
----------------

The *S. sonnei* isolates, *E. coli* V.517 and *E. coli* 39R were grown in 5 ml LB broth at 200 rpm, 37°C overnight. Plasmid DNAs were extracted by alkaline lysis method \[[@B14]\] and separated by electrophoresis on a 0.8% agarose gel with 0.5x TBE using plasmids from *E. coli* V.517 and *E. coli* 39R as reference size markers. A combined dendrogram of plasmid and antimicrobial susceptibility were generated by BioNumerics Software version 6.0 (Applied Maths, Kortrijk, Belgium), UPGMA type and Dice coefficient with 1.5% optimization and tolerance.

Multiplex PCR for plasmid replicon typing
-----------------------------------------

The *S. sonnei* isolates were examined by PCR using three multiplex primer panels for the presence of 18 replicon plasmids and three singleplex primer pairs for an additional 3 replicon plasmids, ColE, IncU and IncR plasmids (Table [1](#T1){ref-type="table"}). *S. sonnei* isolates and reference plasmids for controls were grown on TSA plates at 37°C overnight and were extracted for genomic DNA using DNeasy Blood and Tissue Kit (QIAGEN, Valencia, CA, USA). The reference plasmid controls were kindly provided by Dr. Alessandra Carottoli. PCR reactions were performed as previously described \[[@B15],[@B16]\]. Positive controls as well as a negative control without DNA were run with each multiplex primer panel.

###### 

PCR primer sequence

  **Primer**              **Sequence (5'-3')**                  **Location**              **Annealing temperature (°C)**   **Product size (bp)**   **Reference**
  ----------------- -------------------------------- ----------------------------------- -------------------------------- ----------------------- ---------------
  IntF                     GGCATCCAAGCAGCAAGC            5'-CS of class 1 integrons                     58                        varied            \[[@B17]\]
  IntB                     AAGCAGACTTGACCTGAT            3'-CS of class 1 integrons                                                               
  IntI2L                 GTAGCAAACGAGTGACGAAATG                     intI2                               58                          789             \[[@B17]\]
  IntI2R                 CACGGATATGCGACAAAAAGGT                                                                                                   
  IntI2CaF              GATAAAAACAGCCTGACCTCTTC                     intI2                               58                         2433             \[[@B17]\]
  IntI2CaR              CCCACTTGACATCTCATCAATAC        3' region of class 2 integrons                                                             
  ST.GYRA1                TGTCCGAGATGGCCTGAAGC                  DNA gyrase A                            55                          470             \[[@B18]\]
  ST.GYRA12               CGTTGATGACTTCCGTCAG                                                                                                     
  *mphA*F                   AACTGTACGCACTTGC          *macrolide* 2'-phosphotransferase                 50                          837             \[[@B19]\]
  *mphA*R                   GGTACTCTTCGTTACC                                                                                                      
  **Multiplex 1**                                                                                                                                         
  B/O_F                  GCGGTCCGGAAAGCCAGAAAAC                     RNAI                                60                          159             \[[@B15]\]
  B/O_R                  TCTGCGTTCCGCCAAGTTCGA                                                                                                    
  FIC_F                  GTGAACTGGCAGATGAGGAAGG                     repA2                               60                          262             \[[@B15]\]
  FIC_R                 TTCTCCTCGTCGCCAAACTAGAT                                                                                                   
  A/C_F                 GAGAACCAAAGACAAAGACCTGGA                    repA                                60                          465             \[[@B15]\]
  A/C_R                 ACGACAAACCTGAATTGCCTCCTT                                                                                                  
  P_F                  CTATGGCCCTGCAAACGCGCCAGAAA                  iterons                              60                          534             \[[@B15]\]
  P_R                     TCACGCGCCAGGGCGCAGCC                                                                                                    
  T_F                   TTGGCCTGTTTGTGCCTAAACCAT                    repA                                60                          750             \[[@B15]\]
  T_R                   CGTTGATTACACTTAGCTTTGGAC                                                                                                  
  **Multiplex 2**                                                                                                                                         
  K/B_F                  GCGGTCCGGAAAGCCAGAAAAC                     RNAI                                60                          160             \[[@B15]\]
  K/B_R                   TCTTTCACGAGCCCGCCAAA                                                                                                    
  W_F                    CCTAAGAACAACAAAGCCCCCG                     repA                                60                          242             \[[@B15]\]
  W_R                     GGTGCGCGGCATAGAACCGT                                                                                                    
  FIIA_F                   CTGTCGTAAGCTGATGGC                       repA                                60                          270             \[[@B15]\]
  FIIA_R                  CTCTGCCACAAACTTCAGC                                                                                                     
  FIA_F                 CCATGCTGGTTCTAGAGAAGGTG                    iterons                              60                          462             \[[@B15]\]
  FIA_R                 GTATATCCTTACTGGCTTCCGCAG                                                                                                  
  FIB_F                 GGAGTTCTGACACACGATTTTCTG                    repA                                60                          702             \[[@B15]\]
  FIB_R                  CTCCCGTCGCTTCAGGGCATT                                                                                                    
  Y_F                  AATTCAAACAACACTGTGCAGCCTG                    repA                                60                          765             \[[@B15]\]
  Y_R                  GCGAGAATGGACGATTACAAAACTTT                                                                                                 
  **Multiplex 3**                                                                                                                                         
  I1_F                    CGAAAGCCGGACGGCAGAA                       RNAI                                60                          139             \[[@B15]\]
  I1_R                   TCGTCGTTCCGCCAAGTTCGT                                                                                                    
  Frep_F                  TGATCGTTTAAGGAATTTTG                    RNAI/repA                             60                          270             \[[@B15]\]
  Frep_R                  GAAGATCAGTCACACCATCC                                                                                                    
  X_F                 AACCTTAGAGGCTATTTAAGTTGCTGAT                  ori γ                               60                          376             \[[@B15]\]
  X_R                TGAGAGTCAATTTTTATCTCATGTTTTAGC                                                                                               
  HI1_F                 GGAGCGATGGATTACTTCAGTAC                   parA-parB                             60                          471             \[[@B15]\]
  HI1_R                  TGCCGTTTCACCTCGTGAGTA                                                                                                    
  N_F                     GTCTAACGAGCTTACCGAAG                      repA                                60                          559             \[[@B15]\]
  N_R                     GTTTCAACTCTGCCAAGTTC                                                                                                    
  HI2_F                TTTCTCCTGAGTCACCTGTTAACAC                   iterons                              60                          644             \[[@B15]\]
  HI2_R                  GGCTCACTACCGTTGTCATCCT                                                                                                   
  L/M_F                GGATGAAAACTATCAGCATCTGAAG                 repA, B, C                             60                          785             \[[@B15]\]
  L/M_R                  CTGCAGGGGCGATTCTTTAGG                                                                                                    
  oricolE_F                GTTCGTGCATACAGTCCA                   ColE plasmids                           60                          187             \[[@B16]\]
  oricolE_R                GGCGAAACCCGACAGGAC                                                                                                     
  IncR_F                 TCGCTTCATTCCTGCTTCAGC                  IncR plasmids                           60                          251             \[[@B16]\]
  IncR_R                 GTGTGCTGTGGTTATGCCTCA                                                                                                    
  IncU_F                  TCACGACACAAGCGCAAGGG                  IncU plasmids                           60                          843             \[[@B16]\]
  IncU_R                  TCATGGTACATCTGGGCGC                                                                                                     

Amplification of Integrons, DNA gyrase A gene and azithromycin resistance gene (*mphA*)
---------------------------------------------------------------------------------------

The *S. sonnei* isolates were grown on TSA plates at 37°C overnight and purified for genomic DNA extracted using DNeasy Blood and Tissue Kit (QIAGEN, Valencia, CA, USA). DNA templates were kept at -20°C before use. Extracted DNA was amplified for class 1 and class 2 integrons, DNA gyrase A gene and azithromycin resistance gene (*mphA*) by PCR (Table [1](#T1){ref-type="table"}), as previously described \[[@B17]-[@B19]\].

Restriction fragment length polymorphism (RFLP)
-----------------------------------------------

RFLP was performed on amplified DNA of class 2 integrons of the *S. sonnei* isolates by using Int2CaF and Int2CaR primers (Table [1](#T1){ref-type="table"}) and PCR conditions as previously described \[[@B17]\]. Amplified product was purified by Wizard® SV Gel and PCR Clean-Up System (Promega, Madison, WI, USA) and digested with *Xba*I (Roche, Indianapolis, IN, USA) at 37°C for 2 hours. The restriction fragments were detected on a 1.5% agarose gel by electrophoresis with 0.5X TBE buffer. Two-log DNA ladder (BioLabs, Ipswich, MA, USA) was used as a standard DNA marker.

Sequencing and bioinformatics analysis
--------------------------------------

The amplified PCR products of *S. sonnei* isolates, class 1 integrons, class 2 integrons and the gyrase A gene were purified by Wizard® SV Gel and PCR Clean-Up System and were sequenced (Macrogen, Korea). The nucleotide sequences were analyzed with BLAST software (<http://www.ncbi.nlm.nih.gov/BLAST>).

Results
=======

*Shigella sonnei* isolates
--------------------------

During the surveillance study from March 2011 to February 2013 at JDWNRH in Thimphu, Bhutan, a total of 1,133 children from 3 months to 5 years of age were studied. This included 571 children with diarrhea and 562 non-diarrhea controls. The percentage of *Shigella* spp*.* detected were 70.9% (56/79) of *S. sonnei*, 19.0% (15/79) of *S. flexneri*, 8.9% (7/79) of *S. boydii* and 1.2% (1/79) of *S. dysenteriae*. An epidemic curve of the number of cases per month of *S. sonnei* from March 2011 to February 2013 was created, a total of 56 *S. sonnei* isolates were 51 isolates from cases and 5 isolates from controls (Figure [1](#F1){ref-type="fig"}). During the apparent outbreak of *S. sonnei* in Thimphu, Bhutan in June and July 2011, a total of 25 *S. sonnei* were isolated from cases and 4 *S. sonnei* were isolated from asymptomatic controls. The other 27 *S. sonnei* isolates were sporadically found from March 2011 to February 2013. All 29 *S. sonnei* isolates during the outbreak period were characterized in this study. Four *S. sonnei* from Nepal in 2007--2008 and five *S. sonnei* from Thailand in 2008 isolated previously at AFRIMS were included in this study for comparison.

![**Epidemic curve of*S. sonnei*isolates in Thimphu, Bhutan from March 2011 to February 2013.**](1756-0500-7-95-1){#F1}

Multidrug-resistant *Shigella sonnei* in Bhutan
-----------------------------------------------

In this study, the 29 *S. sonnei* isolates from Thimphu, Bhutan were resistant to NA, CIP, SXT, S and TE by disk diffusion assay (Table [2](#T2){ref-type="table"}). These 29 isolates had an MIC of NA (\>256 μg/ml) and CIP (3.0-4.0 μg/ml) by E-test confirming the resistance described by disk diffusion assay. All 29 isolates were susceptible to AZM by disk diffusion assay. The MIC range of AZM by E-test was 3.0-4.0 μg/ml corresponding to intermediate susceptibility to AZM (Table [2](#T2){ref-type="table"}).

###### 

**Characteristics of*S. sonnei*isolates from Bhutan, Nepal and Thailand**

  **Study site**    **Number of isolates**   **Resistance pattern**   **MIC (μg/ml)**   **Integrons**   **DNA Gyrase A mutation**   **Replicon plasmid**                        
  ---------------- ------------------------ ------------------------ ----------------- --------------- --------------------------- ---------------------- ---------- ---------- -----------
  Bhutan                      19              S, SXT, TE, NA, CIP         3.0-4.0           \>256                3.0-4.0                  Class 2          Ser83Leu   Asp87Gly     ColE
  Bhutan                      9               S, SXT, TE, NA, CIP         3.0-4.0           \>256                3.0-4.0                  Class 2          Ser83Leu   Asp87Gly   B/O, ColE
  Bhutan                      1               S, SXT, TE, NA, CIP           4.0             \>256                  3.0                    Class 2          Ser83Leu   Asp87Gly   I1, ColE
  Nepal                       1               S, SXT, TE, NA, CIP           4.0             \>256                  4.0                    Class 2          Ser83Leu   Asp87Gly     ColE
  Nepal                       2                  S, SXT, TE, NA           3.0-4.0           \>256              0.190-0.125                Class 2          Ser83Leu     Neg        ColE
  Nepal                       1                        S                    3.0              3.0                  0.008                     Neg              Neg        Neg        ColE
  Thailand                    1                S, SXT, TE, NA, AM           3.0             \>256                 0.190                     Neg            Ser83Leu     Neg      B/O, ColE
  Thailand                    1                  S, SXT, TE, AM             3.0              3.0                  0.004                     Neg              Neg        Neg      I1, ColE
  Thailand                    2                S, SXT, TE, NA, AM         3.0-4.0            128                  0.004                   Class 2            Neg      Asp87Tyr   I1, ColE
  Thailand                    1                 S, SXT, TE, NA,             4.0             \>256                 0.004                   Class 2          Ser83Leu     Neg        ColE

AZM, azithromycin; NA, nalidixic acid; CIP, ciprofloxacin; AM, ampicillin; SXT, trimethoprim-sulfamethoxazole; CRO, ceftriaxone; S, streptomycin; TE, tetracycline; Ser, Serine; Leu, Leucine; Asp, Aspartic acid; Gly, Glycine; Tyr, Tyrosine; Neg, negative result.

PFGE patterns and plasmid patterns analysis
-------------------------------------------

At 80% similarity, the PFGE patterns of all 38 isolates clustered into 4 groups (Figure [2](#F2){ref-type="fig"}). Groups 1, 3 and 4 included *S. sonnei* from Nepal and Thailand. Group 2 consisted of the 29 *S. sonnei* isolates from Bhutan and 1 isolate from Nepal. *S. sonnei* isolates from Bhutan were closely related within the subgroup with 97-100% similarity. All 30 isolates in group 2 had a pattern of resistance to NA, CIP, SXT, S and TE (Figure [2](#F2){ref-type="fig"}).

![**Dendrogram obtained by cluster analysis of the PFGE patterns of*S. sonnei*from Bhutan, Nepal and Thailand combined with antibiotic susceptibility.** AZM, azithromycin; NA, nalidixic acid; CIP, ciprofloxacin; AM, ampicillin; SXT, trimethoprim-sulfamethoxazole; CRO, ceftriaxone; S, Streptomycin; TE, tetracycline; S, susceptible; R, resistant; ND, not determined.](1756-0500-7-95-2){#F2}

*S. sonnei* from Bhutan contained various plasmids with sizes ranging from 0.35 Kb to 98 Kb. Nine isolates from Bhutan contained larger plasmids sized from 32 Kb to 98 Kb similar to 1 isolate from Nepal and 4 isolates from Thailand. Most isolates from all three sites contained variable plasmids sized from 0.35 Kb to 25 Kb. At 62% similarity, dendrogram of the plasmid DNA patterns of *S. sonnei* was classified into 4 groups. Group 2 consisted of the 29 *S. sonnei* isolates from Bhutan and 1 isolate from Nepal. Groups 1, 3 and 4 included *S. sonnei* isolates from Thailand and Nepal with variable antimicrobial susceptibility patterns \[see Additional file [1](#S1){ref-type="supplementary-material"}\].

Replicon typing
---------------

*S. sonnei* isolates were classified for plasmid incompatibility by PCR-based replicon typing (PBRT) with 21 primer pairs (B/O, FIC, A/C, P, T, K/B, W, FIIA, FIA, FIIB, Y, I1, Frep, X, HI1, N, HI2, L/M, ColE, IncR and IncU plasmid. All 38 isolates from Bhutan, Nepal, and Thailand carried the ColE plasmid. Nine isolates from Bhutan and one isolate from Thailand carried B/O plasmid. One isolate from Bhutan and three isolates from Thailand carried the I1 plasmid (Table [2](#T2){ref-type="table"}).

PCR and sequencing analysis
---------------------------

The *gyrA* genes of the 38 *S. sonnei* isolates from Bhutan, Nepal and Thailand were amplified. The sequence analysis of the 470 bp amplified products from 29 *S. sonnei* isolates from Bhutan and one isolate from Nepal revealed the presence of two point mutations in the GyrA subunit (Ser83Leu and Asp87Gly) (Table [2](#T2){ref-type="table"}). However, no amplified products were observed for the *mph*A gene in all 38 *S. sonnei* isolates compared to an azithromycin resistant Enteroaggregative *E. coli* control.

All 38 *S. sonnei* isolates had amplified products of class 1 integrons of approximately 700 bp. By DNA sequencing, the amplified products of 5 selected *S. sonnei* isolates from Bhutan showed no homologies to published gene cassettes of class 1 integrons but had 99% identity of conserved hypothetical protein *S. sonnei* Ss046 in the NCBI database. Thus, *S. sonnei* in Bhutan did not contain resistance genes in class 1 integrons. The class 2 integrons of 38 *S. sonnei* isolates were also amplified. The amplified products of 29 isolates from Bhutan and 3 isolates from Nepal were of similar size (2.4 Kb) but differed from the class 2 integrons in the 3 Thailand isolates (\~3-4 Kb). The DNA sequence alignment of class 2 integrons from 5 selected *S. sonnei* isolates from Bhutan had homology to dihydrofolate reductase (*dfrA1*)*,* streptothricin acetyltransferase (*sat1*) and aminiglycoside adenyltransferase (*aadA1*) associated with resistance to trimethoprim, streptothricin and streptomycin/spectinomycin, respectively. Moreover, RFLP of amplified products of the class 2 integrons in all 38 isolates with *Xba*I, yielded the same DNA restricted-fragments of approximately 1,600 bp and 800 bp in 29 *S. sonnei* isolates from Bhutan and 1 isolate from Nepal. The other Nepal and Thailand isolates had uncut DNA or undetectable bands.

Discussion
==========

Over the last few years, MDR patterns in *Shigella* spp*.* have been reported in many countries \[[@B20]\]. In this study, all *S. sonnei* isolates from children in Thimphu, Bhutan in June and July, 2011 were resistant to multiple drugs like ciprofloxacin, nalidixic acid, trimethoprim-sulfamethoxazole, streptomycin and tetracycline. The MDR patterns of the *S. sonnei* from Bhutan differed from neighboring countries. In India, antimicrobial resistance in *S. sonnei* is more common than in other enteric bacteria with resistant to azithromycin, ciprofloxacin, furazolidone, nalidixic acid, norfloxacin, ofloxacin, trimethoprim-sulfamethoxazole, tetracycline \[[@B21]\]. In Bangladesh, most of *S. sonnei* isolates were resistant to nalidixic acid, sulfamethoxazole-trimethoprim, ampicillin, streptomycin and tetracycline \[[@B22]\]. In China, the antimicrobial resistance profiles of *S. sonnei* were nalidixic acid, piperacilline and ciprofloxacin \[[@B23]\]. In Nepal, *S. sonnei* isolates were resistant to azithromycin, ciprofloxacin, ceftriaxone, ampicillin, nalidixic acid and trimethoprim-sulfamethoxazole \[[@B24]\].

*Shigellae* usually harbor various plasmids, such as those required for bacterial invasion into the host intestinal epithelial cells and antibiotic resistance, which may range in number from two to as many as ten in one strain \[[@B25]\]. The PFGE and plasmid patterns of *S. sonnei* from Thimphu, Bhutan suggested clonality. *S. sonnei* in Thimphu, Bhutan carried the typical number of variable plasmid sizes from 0.35 Kb to 98 Kb. These *S. sonnei* also contained the typical number of plasmids from seven to ten in one strain. The ability to recognize and categorize plasmids in homogeneous groups on the basis of their phylogenetic relatedness is helpful to analyze their distribution in nature and their relationship to host cells and to discover their evolutionary origins \[[@B26]\]. Classification of plasmids into incompatibility groups is desirable because specific plasmid types have been associated with virulence and/or antimicrobial resistance \[[@B15]\]. The plasmid replicon typing results showed that all *S. sonnei* isolates from Thimphu, Bhutan carried ColE plasmid as the same as control isolates from Nepal and Thailand. ColE plasmid which contains genes that code for colicin protein (bacteriocin protein) that can kill other bacteria and can replicate in the absence of de novo protein synthesis \[[@B26],[@B27]\]. Furthermore, ColE plasmids co-resided with B/O or I1 in several *S. sonnei* isolates. The simultaneous presence of the ColE plasmid with additional plasmids belonging to the I1, B/O or A/C groups within the same parental strain suggested that the latter plasmids can participate in the mobilization of the ColE plasmids. B/O and I1 plasmid are plasmid incompatibility (Inc) groups capable of carrying transfer, MDR, and virulence functions \[[@B28]\].

Previous studies reported on the frequent incidence of class 2 integrons in *Shigella* isolates worldwide. DNA sequencing of the class 2 integrons in this study showed homologies with class 2 integrons but no homologies to published gene cassettes of class 1 integrons. In this study, *S. sonnei* from Thimphu, Bhutan carried three classic gene cassettes (2,433 bp) in transposon Tn7 corresponding to previous results. *S. sonnei* isolates from Korea carried class 2 integrons (2,224 bp) that consist of Tn7 with *dfrA1*, *sat1* and *aadA1*\[[@B29]\]. In Japan, two types of class 2 integrons in *S. sonnei* isolates were previously identified. One was the classical type (2,158 bp) with *dfrA1*, *sat1* and *aadA1*. The other type was shorter (1,313 bp) and carried only two gene cassettes with *dfrA1* and *sat1*\[[@B20]\]. In China, a 3,361 bp DNA fragment was found in *S. sonnei* with gene cassette arrays in this class 2 integrons of *dfrA1*, *sat1*, *aadA1* and *orfX*\[[@B17]\].

Nalidixic acid resistance among enteric bacteria is related to the presence of a single amino-acid substitution at either position 83 or position 87 of GyrA, while resistance to ciprofloxacin is related to the presence of at least one additional substitution in GyrA \[[@B30]\]. In this study, *S. sonnei* in Thimphu, Bhutan presented two mutations at position 83 (Serine to Leucine) and position 87 (Aspartic acid to Glycine) related to NA and CIP resistance. These two mutations conferred extremely high resistance to NA in *S. sonnei* in Bhutan that has been reported previously from *S. sonnei* isolates in Japan \[[@B31]\]. The expression of *mphA* gene is related to the decrease of AZM susceptibility \[[@B19]\]. In the USA, isolates with a susceptibility at 8 mg/L lacked *mphA* gene but isolates with higher MICs (\>64 mg/L) to AZM reportedly contained a plasmid-encoded *mphA* gene \[[@B19]\]. In this study, MIC range of AZM was 3.0-4.0 μg/ml and PCR results showed that *mph*A gene was not present.

Conclusions
===========

This study described the recent antimicrobial resistance among *S. sonnei* strains isolated from Thimphu, Bhutan in June and July, 2011 and molecular characterization of these *S. sonnei*. Plasmid patterns, PFGE and uniform MDR suggest that these 29 *S. sonnei* isolates are closely related. All *S. sonnei* isolates carried common ColE plasmid that co-resided with B/O or I1 plasmid in many isolates. Further study and comparison with other isolates from the region may provide information on the development and continued spread of antibiotic resistance in *S. sonnei*.
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